In a significant development in the field of obesity treatment, Lilly’s Zepbound (tirzepatide) has shown remarkable results in the SURMOUNT-4 study. Published in The Journal of the American Medical Association (JAMA), the study details how Zepbound injection led to superior mean percent changes in body weight compared to placebo among adults with obesity or overweight, […]
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. Both studies successfully met all primary and key secondary objectives, showcasing the effectiveness of tirzepatide over a placebo. The results saw participants on tirzepatide, after […]
